Madagascar vs Mongolia: Share of the population living with HIV receiving antiretroviral therapy
Madagascar
29.3%
in 2024
Mongolia
40.6%
in 2024
Madagascar rank
142nd
Mongolia rank
139th
Share of the population living with HIV receiving antiretroviral therapy over time
- Madagascar
- Mongolia
How they compare
Mongolia currently reports 40.6% against 29.3% in Madagascar, a difference of 11.3%.
That makes Mongolia's figure about 1.4 times Madagascar's.
Across all 35 years both countries report, Mongolia has been ahead every year.
Madagascar ranks 142nd and Mongolia ranks 139th of 149 countries.
Mongolia has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Madagascar | Mongolia | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0.0% | 0.0% | 0.0% | — |
| 2000s | 0.4% | 0.7% | 0.4% | Mongolia |
| 2010s | 3.7% | 23.0% | 19.3% | Mongolia |
| 2020s | 18.9% | 38.6% | 19.8% | Mongolia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of the population living with hiv receiving antiretroviral therapy, Madagascar or Mongolia?
- Mongolia, at 40.6% against 29.3% in Madagascar as of 2024.
- What is the difference in share of the population living with hiv receiving antiretroviral therapy between Madagascar and Mongolia?
- 11.3%, with Mongolia ahead.
- How many years of comparable data are there for Madagascar and Mongolia?
- 35 years are reported by both, from 1990 to 2024.
- How do Madagascar and Mongolia rank globally for share of the population living with hiv receiving antiretroviral therapy?
- Madagascar ranks 142nd and Mongolia ranks 139th of 149 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as Share of the population living with HIV receiving antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of individuals diagnosed with HIV who are currently receiving antiretroviral therapy. This is the central estimate.